• Cardiomyocytes Differentiation

Cardiomyocytes Differentiation

Applied StemCell provides top quality service for directed-differentiation of iPSCs into cardiomyocytes using our proprietary induction protocol and reagents. We deliver ready-to-use, functional cardiomyocytes that are desirable in vitro models for high content toxicity and drug screening, and cell regeneration research. They are a feasible and physiologically relevant alternative to embryonic stem cell, primary cells, and animal models. 

We can generate differentiated cardiomyocytes from iPSC derived from healthy or disease patient samples.

Products and Services
Support Materials
Technical Details

 

iPSC Differentiation to Cardiomyocytes

 

Timelines: 4-6 weeks

  1. Recovery, Expansion and Validation of iPSCs/ESCs: estimated 3 weeks
  2. Cardiomyocytes Differentiation: estimated 2-4 weeks
  3. Characterization of differentiated cells by immunocytochemical (ICC) staining: 2 biomarkers (cTNT; SMA): estimated 2-4 days

Deliverables:

  1. Lineage-committed cardiomyocytes differentiated from iPSCs. 
  2. Report containing results and data:
    1. Phase contrast images of parental iPSC lines after expansion (milestone 1); and differentiated cardiomyocytes
    2. Videos of beating cardiomyocytes (before cryopreservation)
    3. Antibody staining images of cardiomyocytes using anti-TNT anti-SMA antibodies
    4. Freeze-thaw viability and mycoplasma testing

iPSC Differentiation to Blood Lineage Cells:

Ask us about directed differentiation of your iPSCs into hematopoietic stem cells (HSCs) and blood cells. Avoid sourcing problems associated with HSC procurement, and have a consistent and continuous source of mature human blood cells that are otherwise hard to obtain and maintain. 

Applications: hematopoiesis, cancer immunotherapy, autoimmune diseases/ transplant graft rejection, and drug screening.

Have Questions?

An Applied StemCell technical expert is happy to help, contact us today!